Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
OC
MCID: OVR042
MIFTS: 88

Ovarian Cancer (OC)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Ovarian Cancer

About this section

MalaCards integrated aliases for Ovarian Cancer:

Name: Ovarian Cancer 57 12 74 20 43 58 73 36 29 54 6 42 3 15
Ovarian Carcinoma 12 20 43 54 6 15 17 71
Ovarian Neoplasm 12 17 71
Malignant Neoplasm of Ovary 71 32
Epithelial Ovarian Cancer 73 71
Neoplasm of Ovary 29 6
Ovarian Neoplasms 54 44
Ovarian Cancers 6 15
Primary Malignant Neoplasm of Ovary 71
Malignant Neoplasm of the Ovary 43
Malignant Tumor of the Ovary 43
Malignant Tumour of Ovary 12
Ovarian Cancer, Somatic 57
Malignant Ovarian Tumor 12
Ovarian Malignant Tumor 58
Primary Ovarian Cancer 12
Cancer of the Ovary 43
Tumor of the Ovary 12
Ovarian Carcinomas 15
Cancer, Ovarian 39
Ovary Neoplasm 12
Oc 73

Characteristics:

Orphanet epidemiological data:

58
ovarian cancer
Prevalence: 1-5/10000 (Europe);

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
somatic mutation


HPO:

31
ovarian cancer:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Reproductive diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 32
Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:2394 DOID:4001
OMIM® 57 167000
KEGG 36 H00027
ICD9CM 34 183.0
MeSH 44 D010051
NCIt 50 C4984 C7431
ICD10 32 C56
UMLS via Orphanet 72 C1140680
Orphanet 58 ORPHA213500
UMLS 71 C0029925 C0677886 C0919267 more
Sources

Summaries for Ovarian Cancer

About this section
MedlinePlus Genetics : 43 Ovarian cancer is a disease that affects women. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.The most common form of ovarian cancer begins in epithelial cells, which are the cells that line the surfaces and cavities of the body. These cancers can arise in the epithelial cells on the surface of the ovary. However, researchers suggest that many or even most ovarian cancers begin in epithelial cells on the fringes (fimbriae) at the end of one of the fallopian tubes, and the cancerous cells migrate to the ovary.Cancer can also begin in epithelial cells that form the lining of the abdomen (the peritoneum). This form of cancer, called primary peritoneal cancer, resembles epithelial ovarian cancer in its origin, symptoms, progression, and treatment. Primary peritoneal cancer often spreads to the ovaries. It can also occur even if the ovaries have been removed. Because cancers that begin in the ovaries, fallopian tubes, and peritoneum are so similar and spread easily from one of these structures to the others, they are often difficult to distinguish. These cancers are so closely related that they are generally considered collectively by experts.In about 10 percent of cases, ovarian cancer develops not in epithelial cells but in germ cells, which are precursors to egg cells, or in hormone-producing ovarian cells called granulosa cells.In its early stages, ovarian cancer usually does not cause noticeable symptoms. As the cancer progresses, signs and symptoms can include pain or a feeling of heaviness in the pelvis or lower abdomen, bloating, feeling full quickly when eating, back pain, vaginal bleeding between menstrual periods or after menopause, or changes in urinary or bowel habits. However, these changes can occur as part of many different conditions. Having one or more of these symptoms does not mean that a woman has ovarian cancer.In some cases, cancerous tumors can invade surrounding tissue and spread to other parts of the body. If ovarian cancer spreads, cancerous tumors most often appear in the abdominal cavity or on the surfaces of nearby organs such as the bladder or colon. Tumors that begin at one site and then spread to other areas of the body are called metastatic cancers.Some ovarian cancers cluster in families. These cancers are described as hereditary and are associated with inherited gene mutations. Hereditary ovarian cancers tend to develop earlier in life than non-inherited (sporadic) cases.Because it is often diagnosed at a late stage, ovarian cancer can be difficult to treat; it leads to the deaths of about 14,000 women annually in the United States, more than any other gynecological cancer. However, when it is diagnosed and treated early, the 5-year survival rate is high.

MalaCards based summary : Ovarian Cancer, also known as ovarian carcinoma, is related to hereditary breast ovarian cancer syndrome and breast cancer, and has symptoms including pelvic pain An important gene associated with Ovarian Cancer is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are MicroRNAs in cancer and ERK Signaling. The drugs Tranexamic Acid and Iron have been mentioned in the context of this disorder. Affiliated tissues include ovary, breast and prostate, and related phenotypes are breast carcinoma and abnormality of metabolism/homeostasis

Disease Ontology : 12 A female reproductive organ cancer that is located in the ovary.

GARD : 20 Ovarian cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the ovaries. Many people with early ovarian cancer have no signs or symptoms of the condition. When present, symptoms are often nonspecific and blamed on other, more common conditions. Most cases of ovarian cancer occur sporadically in people with little to no family history of the condition; however, approximately 10-25% of ovarian cancers are thought to be "hereditary." Although the underlying genetic cause of some hereditary cases is unknown, many are part of a hereditary cancer syndrome (such as BRCA1 or BRCA2 hereditary breast and ovarian cancer syndrome, Lynch syndrome and Peutz-Jeghers syndrome) and are inherited in an autosomal dominant manner. The best treatment options for ovarian cancer depend on many factors including the subtype and stage of the condition, but may include surgery, chemotherapy, radiation therapy, and/or targeted therapy (such as monoclonal antibody therapy).

OMIM® : 57 Ovarian cancer, the leading cause of death from gynecologic malignancy, is characterized by advanced presentation with loco-regional dissemination in the peritoneal cavity and the rare incidence of visceral metastases (Chi et al., 2001). These typical features relate to the biology of the disease, which is a principal determinant of outcome (Auersperg et al., 2001). Epithelial ovarian cancer is the most common form and encompasses 5 major histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Epithelial ovarian cancer arises as a result of genetic alterations sustained by the ovarian surface epithelium (Stany et al., 2008; Soslow, 2008). (167000) (Updated 05-Mar-2021)

MedlinePlus : 42 The ovaries are part of the female reproductive system. They produce a woman's eggs and female hormones. Each ovary is about the size and shape of an almond. Cancer of the ovary is not common, but it causes more deaths than other female reproductive cancers. The sooner ovarian cancer is found and treated, the better your chance for recovery. But ovarian cancer is hard to detect early. Women with ovarian cancer may have no symptoms or just mild symptoms until the disease is in an advanced stage. Then it is hard to treat. Symptoms may include A heavy feeling in the pelvis Pain in the lower abdomen Bleeding from the vagina Weight gain or loss Abnormal periods Unexplained back pain that gets worse Gas, nausea, vomiting, or loss of appetite To diagnose ovarian cancer, doctors do one or more tests. They include a physical exam, a pelvic exam, lab tests, ultrasound, or a biopsy. Treatment is usually surgery followed by chemotherapy. NIH: National Cancer Institute

CDC : 3 Cancer is a disease in which abnormal cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. Ovarian cancer is a group of diseases that originates in the ovaries, or in the related areas of the fallopian tubes and the peritoneum. Women have two ovaries that are located in the pelvis, one on each side of the uterus. The ovaries make female hormones and produce eggs. Women have two fallopian tubes that are a pair of long, slender tubes on each side of the uterus. Eggs pass from the ovaries through the fallopian tubes to the uterus. The peritoneum is the tissue lining that covers organs in the abdomen. When ovarian cancer is found in its early stages, treatment works best. Ovarian cancer often causes signs and symptoms, so it is important to pay attention to your body and know what is normal for you. Symptoms may be caused by something other than cancer, but the only way to know is to see your doctor, nurse, or other health care professional. Some mutations (changes in genes) can raise your risk for ovarian cancer. Mutations in the breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2), and those associated with Lynch syndrome, raise ovarian cancer risk. Ovarian cancers come in a variety of different tumor types. The most common tumor type is high-grade serous carcinoma, occurring in about 70% of ovarian cancer cases.

KEGG : 36 Ovarian cancer is the sixth most common cancer and the fifth leading cause of cancer-related death among women in developed countries. Approximately 90% of human ovarian cancer arises within the ovarian surface epithelium (OSE), with the rest originating from granulosa cells or, rarely, stroma or germ cells. Ovarian epithelial tumors are divided into mucinous, serous, endometrioid, and clear cell subtypes. Approximately 10% of ovarian cancers arise in women who have inherited mutations in cancer susceptibility genes (BRCA1 or BRCA2). The vast majority of ovarian cancers are sporadic, resulting from the accumulation of genetic damage over a lifetime. Several specific genes involved in ovarian carcinogenesis have been identified, including the p53 tumor suppressor gene and ERBB2 and PIK3CA oncogenes.

Novus Biologicals : 55 Tumor markers can be found in the body when cancer is present. They are most often found in the blood or urine, but can also be found in tumors and other tissues. High level of the tumor marker CA125 in the blood strongly suggests ovarian cancer. CA125 is an antigen present on 80% of non-mucinous ovarian carcinomas.

UniProtKB/Swiss-Prot : 73 Ovarian cancer: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.

Wikipedia : 74 Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the... more...

Sources

Related Diseases for Ovarian Cancer

About this section

Diseases in the Ovarian Cancer family:

Ovarian Cancer 1 Familial Ovarian Cancer

Diseases related to Ovarian Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1307)
# Related Disease Score Top Affiliating Genes
1 hereditary breast ovarian cancer syndrome 34.9 TP53 RAD51D RAD51C PTEN PALB2 MSH6
2 breast cancer 34.7 TP53 RAD51D RAD51C PTEN PIK3CA PALB2
3 lynch syndrome 34.3 TP53 RAD51D RAD51C PTEN PIK3CA PALB2
4 pancreatic cancer 34.3 TP53 PTEN PIK3CA PALB2 MAP3K1 ERBB2
5 breast-ovarian cancer, familial 1 34.2 RAD51C PALB2 MSH6 BRCA2 BRCA1
6 fallopian tube carcinoma 33.7 TP53 RAD51D RAD51C PTEN PALB2 ERBB2
7 endometrial cancer 33.7 TP53 PTEN PIK3CA MSH6 ERBB2 CTNNB1
8 adenocarcinoma 33.6 TP53 PTEN PIK3CA MSH6 ERBB2 CTNNB1
9 ovary adenocarcinoma 33.6 TP53 PTEN PIK3CA ERBB2 CTNNB1 CDH1
10 ovary epithelial cancer 33.5 TP53 PTEN PIK3CA ERBB2 CTNNB1 CDH1
11 serous cystadenocarcinoma 33.4 TP53 PTEN PIK3CA ERBB2 BRCA2 BRCA1
12 ovarian disease 33.4 TP53 PTEN ERBB2 BRCA2 BRCA1 AKT1
13 li-fraumeni syndrome 33.3 TP53 RAD51D RAD51C PTEN PIK3CA PALB2
14 hereditary site-specific ovarian cancer syndrome 33.2 RAD51D RAD51C BRCA2 BRCA1
15 fanconi anemia, complementation group a 33.1 TP53 RAD51D RAD51C PTEN PRKN PALB2
16 ovarian clear cell carcinoma 33.1 TP53 PTEN PIK3CA CHEK1
17 cystadenocarcinoma 33.0 TP53 PIK3CA ERBB2 BRCA1 BRAF AKT1
18 prostate cancer 33.0 TP53 PTEN PIK3CA MSH6 ERBB2 CTNNB1
19 lung cancer 33.0 TP53 PTEN PRKN PIK3CA ERBB2 CTNNB1
20 familial ovarian cancer 32.9 BRCA2 BRCA1
21 leukemia, acute myeloid 32.9 TP53 PTEN PIK3CA ERBB2 CTNNB1 CHEK1
22 familiar ovarian carcinoma 32.8 PIK3CA BRCA1
23 colorectal cancer 32.8 TP53 PTEN PIK3CA MSH6 ERBB2 CTNNB1
24 peripheral nervous system disease 32.8 TP53 PTEN PRKN ERBB2 CTNNB1 AKT1
25 ovarian cystadenocarcinoma 32.8 TP53 PTEN PIK3CA ERBB2 CTNNB1 BRCA2
26 skin carcinoma 32.8 TP53 PTEN PIK3CA MSH6 ERBB2 CTNNB1
27 bilateral breast cancer 32.7 PTEN PIK3CA PALB2 MSH6 ERBB2 CDH1
28 melanoma 32.7 TP53 PTEN PIK3CA ERBB2 CTNNB1 CDH1
29 bladder cancer 32.7 TP53 PTEN PIK3CA ERBB2 CTNNB1 CDH1
30 in situ carcinoma 32.6 TP53 PTEN PIK3CA ERBB2 CTNNB1 CDH1
31 adenoma 32.6 TP53 PIK3CA MSH6 CTNNB1 CDH1 BRAF
32 gastric cancer 32.6 TP53 PTEN PIK3CA MSH6 ERBB2 CTNNB1
33 sporadic breast cancer 32.6 TP53 RAD51C PTEN PALB2 ERBB2 CHEK1
34 cowden syndrome 32.5 TP53 RAD51D RAD51C PTEN PIK3CA PALB2
35 ovarian serous cystadenocarcinoma 32.5 TP53 PIK3CA ERBB2 BRAF AKT1
36 primary peritoneal carcinoma 32.4 TP53 ERBB2 BRCA2 BRCA1
37 atypical teratoid rhabdoid tumor 32.4 TP53 CTNNB1 BRCA2
38 cervical cancer 32.4 TP53 PTEN PIK3CA ERBB2 CTNNB1 AKT1
39 neuroblastoma 32.4 TP53 PTEN PIK3CA ERBB2 CTNNB1 CHEK1
40 medulloblastoma 32.4 TP53 PTEN PIK3CA MSH6 ERBB2 CTNNB1
41 glioblastoma 32.4 TP53 PTEN PIK3CA ERBB2 BRCA2 BRAF
42 lung cancer susceptibility 3 32.4 TP53 PIK3CA ERBB2 CTNNB1 CDH1 BRAF
43 esophageal cancer 32.3 TP53 PTEN PIK3CA ERBB2 CTNNB1 CHEK1
44 premature menopause 32.3 TP53 RAD51C PTEN BRCA2 BRCA1 ATM
45 carcinosarcoma 32.3 TP53 PTEN PIK3CA ERBB2 CTNNB1 CDH1
46 renal cell carcinoma, nonpapillary 32.3 TP53 PTEN PIK3CA CDH1 BRAF ATM
47 teratoma 32.3 TP53 PTEN CTNNB1 CDH1 AKT1
48 squamous cell carcinoma 32.2 TP53 PTEN PIK3CA ERBB2 CTNNB1 CDH1
49 female breast cancer 32.2 TP53 PALB2 ERBB2 BRCA2 BRCA1 ATM
50 uterine corpus cancer 32.2 TP53 PTEN PIK3CA MSH6 ERBB2 CTNNB1

Comorbidity relations with Ovarian Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Fallopian Tube Carcinoma Hydronephrosis
Intestinal Obstruction Myofibroma
Neutropenia Paralytic Ileus
Peritoneum Cancer Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Ovarian Cancer:



Diseases related to Ovarian Cancer
Sources

Symptoms & Phenotypes for Ovarian Cancer

About this section

Human phenotypes related to Ovarian Cancer:

31
# Description HPO Frequency HPO Source Accession
1 breast carcinoma 31 HP:0003002
2 abnormality of metabolism/homeostasis 31 HP:0001939
3 dysgerminoma 31 HP:0100621
4 ovarian papillary adenocarcinoma 31 HP:0006774

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Neoplasia:
dysgerminoma
ovarian papillary adenocarcinoma
breast cancer
ovarian cancer
serous ovarian cystadenocarcinoma

Laboratory Abnormalities:
frequent loss of heterozygosity at 6q24-q27

Clinical features from OMIM®:

167000 (Updated 05-Mar-2021)

UMLS symptoms related to Ovarian Cancer:


pelvic pain

GenomeRNAi Phenotypes related to Ovarian Cancer according to GeneCards Suite gene sharing:

26 (show top 50) (show all 85)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 11.15 PIK3CA BRAF
2 Decreased viability GR00055-A-2 11.15 PIK3CA BRAF
3 Decreased viability GR00107-A-1 11.15 MAP3K1
4 Decreased viability GR00221-A-1 11.15 AKT1 CHEK1 PIK3CA CDH1
5 Decreased viability GR00221-A-2 11.15 AKT1 BRCA1 CHEK1 MAP3K1 PIK3CA
6 Decreased viability GR00221-A-3 11.15 AKT1 BRCA1 CHEK1 MAP3K1 ATM ERBB2
7 Decreased viability GR00221-A-4 11.15 AKT1 CHEK1 PIK3CA BRAF ATM ERBB2
8 Decreased viability GR00240-S-1 11.15 CHEK1
9 Decreased viability GR00249-S 11.15 AKT1 CHEK1 BRAF
10 Decreased viability GR00301-A 11.15 BRCA1 CHEK1 BRAF CDH1
11 Decreased viability GR00381-A-1 11.15 CHEK1 BRAF
12 Decreased viability GR00386-A-1 11.15 CHEK1
13 Decreased viability GR00402-S-2 11.15 CHEK1 PIK3CA CDH1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.69 ATM
15 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.69 ATM
16 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.69 ATM
17 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.69 CHEK1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.69 ATM CHEK1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.69 MAP3K1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.69 CHEK1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.69 MAP3K1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-139 10.69 ATM CHEK1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.69 CHEK1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-148 10.69 CHEK1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.69 ATM
26 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.69 ATM
27 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.69 ATM
28 Increased shRNA abundance (Z-score > 2) GR00366-A-160 10.69 ATM
29 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.69 ERBB2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.69 MAP3K1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.69 ERBB2
32 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.69 PRKN
33 Increased shRNA abundance (Z-score > 2) GR00366-A-179 10.69 CHEK1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.69 CHEK1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.69 ERBB2
36 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.69 AKT1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.69 MAP3K1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-26 10.69 CHEK1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.69 ERBB2
40 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.69 ATM
41 Increased shRNA abundance (Z-score > 2) GR00366-A-45 10.69 PRKN
42 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.69 AKT1 CHEK1 ERBB2 MAP3K1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.69 CHEK1 ERBB2
44 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.69 ATM
45 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.69 AKT1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10.69 ATM
47 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.69 MAP3K1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.69 AKT1 ATM CHEK1 ERBB2 MAP3K1
49 Increased shRNA abundance (Z-score > 2) GR00366-A-87 10.69 ERBB2
50 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.69 MAP3K1

MGI Mouse Phenotypes related to Ovarian Cancer:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.53 AKT1 ATM BRAF BRCA1 BRCA2 BRIP1
2 cardiovascular system MP:0005385 10.49 AKT1 ATM BRAF BRCA1 CDH1 CHEK1
3 homeostasis/metabolism MP:0005376 10.45 AKT1 ATM BRAF BRCA1 BRCA2 BRIP1
4 behavior/neurological MP:0005386 10.44 AKT1 ATM BRAF BRCA1 BRCA2 BRIP1
5 growth/size/body region MP:0005378 10.44 AKT1 ATM BRAF BRCA1 BRCA2 CDH1
6 embryo MP:0005380 10.43 AKT1 ATM BRAF BRCA1 BRCA2 CDH1
7 integument MP:0010771 10.42 AKT1 ATM BRAF BRCA1 BRCA2 BRIP1
8 mortality/aging MP:0010768 10.41 AKT1 ATM BRAF BRCA1 BRCA2 CDH1
9 endocrine/exocrine gland MP:0005379 10.39 AKT1 ATM BRAF BRCA1 BRCA2 BRIP1
10 neoplasm MP:0002006 10.31 AKT1 ATM BRAF BRCA1 BRCA2 BRIP1
11 immune system MP:0005387 10.29 AKT1 ATM BRAF BRCA1 BRCA2 CDH1
12 nervous system MP:0003631 10.27 AKT1 ATM BRAF BRCA1 BRCA2 BRIP1
13 limbs/digits/tail MP:0005371 10.18 BRAF BRCA1 BRCA2 BRIP1 CTNNB1 ERBB2
14 digestive/alimentary MP:0005381 10.17 BRAF BRCA1 BRCA2 CDH1 CTNNB1 ERBB2
15 muscle MP:0005369 10.13 AKT1 BRAF BRCA1 CTNNB1 ERBB2 MAP3K1
16 normal MP:0002873 10.02 AKT1 BRAF BRCA1 BRCA2 CDH1 CTNNB1
17 reproductive system MP:0005389 10 AKT1 ATM BRAF BRCA1 BRCA2 BRIP1
18 pigmentation MP:0001186 9.86 BRAF BRCA1 BRIP1 CHEK1 CTNNB1 MAP3K1
19 respiratory system MP:0005388 9.56 AKT1 BRAF BRCA1 CTNNB1 ERBB2 PRKN
20 skeleton MP:0005390 9.36 AKT1 BRAF BRCA1 BRCA2 CTNNB1 ERBB2
Sources

Drugs & Therapeutics for Ovarian Cancer

About this section

Drugs for Ovarian Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 542)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tranexamic Acid Approved Phase 4 1197-18-8 5526
2
Iron Approved Phase 4 7439-89-6 23925 29936
3
Ferrous fumarate Approved Phase 4 141-01-5
4
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
5
Apatinib Phase 4 811803-05-1
6
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
7
Hydralazine Approved Phase 3 86-54-4 3637
8
Epirubicin Approved Phase 3 56420-45-2 41867
9
Amifostine Approved, Investigational Phase 3 20537-88-6 2141
10
Treosulfan Approved, Investigational Phase 3 299-75-2 9296
11
Busulfan Approved, Investigational Phase 3 55-98-1 2478
12
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
13
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
14
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
15
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
16
tannic acid Approved Phase 3 1401-55-4
17
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
18
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
19
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
20
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
21
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
22
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
23
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
24
Selenious acid Approved, Investigational Phase 3 7783-00-8
25
Calcium polycarbophil Approved Phase 3 126040-58-2
26
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
27
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
28
Niraparib Approved, Investigational Phase 3 1038915-60-4 24958200
29
Trabectedin Approved, Investigational Phase 3 114899-77-3 108150
30
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
31
Ifosfamide Approved Phase 3 3778-73-2 3690
32
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
33
Adenosine Approved, Investigational Phase 3 58-61-7 60961
34
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
35
Dimethyl sulfoxide Approved, Vet_approved Phase 2, Phase 3 67-68-5 679
36
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
37
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
38
Rucaparib Approved, Investigational Phase 3 283173-50-2 9931954
39
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
40
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
41
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
42
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
43
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
44
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
45
carbamide peroxide Approved Phase 3 124-43-6
46
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
47
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
48 Kava Approved, Investigational, Nutraceutical Phase 3 9000-38-8
49
Ramosetron Investigational Phase 3 132036-88-5
50
Saracatinib Investigational Phase 2, Phase 3 379231-04-6

Interventional clinical trials:

(show top 50) (show all 1980)
# Name Status NCT ID Phase Drugs
1 A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS Unknown status NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
2 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
3 The Efficacy and Safety of Secondary Prophylaxis Versus ANC< 1000/mm3 Administration of PEG-rhG-CSF in Patients Receiving Cytotoxic Chemotherapy for Gynecologic Malignancies Unknown status NCT03858166 Phase 4 PEG-rhG-CSF
4 Obligatory Post-Registration Open-Label, Non-Comparative Multicenter Study of Efficacy and Tolerance Rate of Caelyx as Monotherapy in Patients With Epithelial Ovarian Cancer, Resistant to Previous Platinum Therapy. Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
5 Diaphragmatic Resection And Gynecological Ovarian Neoplasm Completed NCT03543462 Phase 4
6 Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
7 Tumor Gene Expression Before and After Intraoperative Dexamethasone in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
8 The Multi-center,Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lung Cancer,Head and Neck Cancer,Colorectal Cancer,Ovarian Cancer and the Other Cancer Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
9 A Phase IV Study Comparing the Efficacy of Fosaprepitant to Aprepitant for Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecological Cancer Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
10 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
11 Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies. Completed NCT03384511 Phase 4 Apatinib
12 Comparison of Quality of Life (QoL) Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer Recruiting NCT03164980 Phase 4 Trabectidin (Yondelis)
13 An Indian Multicentric, Open Label, Prospective Phase 4 Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical Practice Recruiting NCT01932125 Phase 4 Bevacizumab
14 Evaluation of PEGylated Doxorubicin Hydrochloride Liposome Injection(Duomeisu®) Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer: A Randomized, Open, Multicenter Clinical Study Recruiting NCT03794778 Phase 4 pegylated liposomal doxorubicin;paclitaxel;Carboplatin
15 A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients With Platinum Sensitive Relapsed Ovarian Cancer Who Are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer With Germline BRCA1/2 Mutation Recruiting NCT04330040 Phase 4 Olaparib
16 Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib in Maintenance After Platine-based Chemotherapy for Patients With Ovarian Cancer Late Relapse : the French GINECO - NiQoLe Study Recruiting NCT03752216 Phase 4 Niraparib
17 Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy Recruiting NCT04352439 Phase 4 Aspirin
18 A Clinical Study Investigating Adverse Drug Reactions and Their Biomarker Correlations in Stage IV Cancer Patients Following Individualized Therapy of Apatinib Recruiting NCT03475589 Phase 4 apatinib
19 A Randomized Controlled Trial of Pre-Operative Treatment With Ferrous Fumarate 300 mg Once Daily Versus Placebo in Newly Diagnoses Gynecologic Oncology Patients Who Are Primary Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
20 An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA). Active, not recruiting NCT02476968 Phase 4 Olaparib
21 Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated NCT02035345 Phase 4 Carboplatin
22 Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer Withdrawn NCT02000739 Phase 4
23 Contrast Enhanced Diffusion-weighted Magnetic Resonance Imaging for Detection of Pathologic Lymph Nodes in Ovarian Cancer - a Feasibility Study. Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavarâ„¢ )
24 Neoadjuvant Chemotherapy (NACT) Followed by Interval Debulking Surgery vs Upfront Surgery Followed by Chemotherapy (CT) in Advanced Epithelial Ovarian Carcinoma (EOC): A Prospective Randomized Study Unknown status NCT00715286 Phase 3
25 Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel for the Treatment of Patients With Recurrent or Primary Advanced Ovarian Cancer : A Randomised Phase 3 Study Unknown status NCT02681432 Phase 3 HIPEC
26 Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer Unknown status NCT00326456 Phase 3 liposomal doxorubicin;carboplatin;paclitaxel
27 A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
28 Multicenter Randomized Survival Study of Monoclonal Antibody Radioimmunotherapy: A Multinational Study in Patients With Ovarian Carcinoma Using the HMFG1 Antibody Labeled With 90Yttrium Unknown status NCT00004115 Phase 3
29 Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line Unknown status NCT01802749 Phase 3 Bevacizumab;Paclitaxel;Carboplatin;pegylated liposomal doxorubicin;Gemcitabine
30 Liposomal Doxorubicin Versus Carboplatin/Paclitaxel in Patients With Ovarian Cancer Recurrence Between 6 and 12 Months After Previous Platinum Based Therapy: Phase III Randomized Multicenter Study Amendment Title Protocol Version 2.0: Phase III International Multicenter Randomized Study Testing the Effect on Survival of Prolonging Platinum-free Interval in Patients With Ovarian Cancer Recurring Between 6 and 12 Months After Previous Platinum Based Chemotherapy. Unknown status NCT00657878 Phase 3 stealth liposomal doxorubicin;carboplatin;paclitaxel;Topotecan;Gemcitabine
31 Phase III Randomized Study of Adjuvant Therapy With a Platinum-Containing Regimen (e.g., CBDCA or CAP: CTX/DOX/CDDP) vs No Adjuvant Therapy in Patients With Fully Resected Early Stage Ovarian Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
32 A Prospective Randomized Phase III Trial of Carboplatin/Gemcitabine/Bevacizumab vs. Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer Unknown status NCT01837251 Phase 3 Carboplatin;PLD
33 Weekly Versus Every 3 Week Carboplatin and Paclitaxel in Patients With Ovarian Cancer: a Phase III Randomized Multicenter Study Unknown status NCT00660842 Phase 3 paclitaxel;carboplatin;paclitaxel
34 Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Cisplatin-Resistant Recurrent Ovarian Cancer. Unknown status NCT00533299 Phase 3 Hydralazine and magnesium valproate;Placebo
35 An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
36 Feasibility of Intraoperative Given Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Cisplatin During a Cytoreductive Surgery in Patients With Recurrent Ovarian, Peritoneal or Fallopian Tube Cancers Unknown status NCT03717610 Phase 3
37 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial. Unknown status NCT02328716 Phase 3 Hipec with Cisplatin
38 Evaluating the Effectiveness of Inquiry Based Stress Reduction (IBSR) Intervention Versus Regular Care of no Treatment on Well-being, Optimism and Health Behavior of BRCA1/2 Carriers: A Randomized Controlled Trial, RCT. Unknown status NCT03162276 Phase 3
39 Stage IIIC Unresectable Epithelial Ovarian/Tubal Cancer With Partial or Complete Response After 1st Line Neoadjuvant Chemotherapy (3 Cycles CBDCA+Paclitaxel): a Phase 3 Prospective Randomized Study Comparing Cytoreductive Surgery + Hyperthermic Intraperitoneal Chemotherapy (CDDP+Paclitaxel) + 3 Cycles CBDCA+Paclitaxel vs Cytoreductive Surgery Alone + 3 Cycles CBDCA+Paclitaxel. Unknown status NCT01628380 Phase 3
40 A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
41 A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
42 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
43 A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors Unknown status NCT00053352 Phase 3 cisplatin;etoposide
44 Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense Weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma Completed NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
45 Phase 2/3 Study of Masitinib in Combination With Gemcitabine Versus Gemcitabine Alone in Advanced/Metastatic Epithelial Ovarian Cancer Patients in Second Line Being Refractory to First Line Platinum Treatment or in Third Line Completed NCT02490488 Phase 2, Phase 3 Masitinib;Gemcitabine;Placebo
46 Impact of Exercise on Ovarian Cancer Prognosis Completed NCT02107066 Phase 3
47 A Randomized Study of Chemotherapy Versus Hormonal Treatment in Patients With Ovarian Cancer Resistant or Refractory to Platinum and Taxane Completed NCT02728622 Phase 3 Tamoxifen;Chemotherapy
48 A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse Completed NCT00849667 Phase 3 MORAb-003 (farletuzumab);MORAb-003 (farletuzumab);0.9% Saline
49 A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00866697 Phase 3 Pazopanib;Placebo
50 Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm Completed NCT01461850 Phase 3 Neoadjuvant chemotherapy + Interval Debulking Surgery

Search NIH Clinical Center for Ovarian Cancer

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Altretamine
Carboplatin
Chlorambucil
Chromic phosphate P32
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
docetaxel
doxorubicin hydrochloride liposome
hydroxyurea
Ifosfamide
Leuprolide
Leuprolide Acetate
Melphalan
Melphalan hydrochloride
Paclitaxel
Topotecan
Topotecan Hydrochloride
Uracil Mustard
vinorelbine
Vinorelbine tartrate

Cochrane evidence based reviews: ovarian neoplasms

Sources

Genetic Tests for Ovarian Cancer

About this section

Genetic tests related to Ovarian Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of Ovary 29 AKT1 CDH1 CTNNB1 OPCML PIK3CA PRKN
2 Ovarian Cancer 29
Sources

Anatomical Context for Ovarian Cancer

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Ovarian Cancer:

19
Ovary

MalaCards organs/tissues related to Ovarian Cancer:

40
Breast, Ovary, Prostate, T Cells, Lung, Lymph Node, Endothelial
Sources

Publications for Ovarian Cancer

About this section

Articles related to Ovarian Cancer:

(show top 50) (show all 42509)
# Title Authors PMID Year
1
OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. 6 57 61
12819783 2003
2
Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. 57 6
12719539 2003
3
Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. 54 61 57
19635727 2010
4
Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. 57 54 61
15619626 2005
5
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. 57 54 61
11179017 2001
6
The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study. 61 57 54
10577927 1999
7
DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. 54 57 61
9620555 1998
8
Whole-genome characterization of chemoresistant ovarian cancer. 61 57
26017449 2015
9
Mutations in BRIP1 confer high risk of ovarian cancer. 61 57
21964575 2011
10
Integrated genomic analyses of ovarian carcinoma. 61 57
21720365 2011
11
MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival. 47 61 54
20461750 2010
12
Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. 57 61
19304784 2009
13
Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. 57 61
19270026 2009
14
Dicer, Drosha, and outcomes in patients with ovarian cancer. 61 57
19092150 2008
15
Histologic subtypes of ovarian carcinoma: an overview. 61 57
18317227 2008
16
The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. 61 57
18026186 2008
17
Classification of ovarian cancer: a genomic analysis. 61 57
18546616 2008
18
MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. 47 61 54
18199536 2008
19
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. 6 54
17611497 2007
20
Mutation of the PIK3CA gene in ovarian and breast cancer. 6 54
15520168 2004
21
Alterations in the common fragile site gene Parkin in ovarian and other cancers. 54 57
14614460 2003
22
Identification of prognostic factors in advanced epithelial ovarian carcinoma. 57 61
11520151 2001
23
Is hereditary site-specific ovarian cancer a distinct genetic condition? 57 61
9450858 1998
24
A cDNA from the ovarian cancer critical region of deletion on chromosome 17p13.3. 61 57
8603384 1996
25
Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. 61 57
8640783 1996
26
A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1. 54 57
7942844 1994
27
A human oncogene of the RAS superfamily unmasked by expression cDNA cloning. 61 6
8052619 1994
28
Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. 61 57
8314147 1994
29
Fine-scale deletion mapping of the distal long arm of chromosome 6 in 70 human ovarian cancers. 57 61
1394208 1992
30
Allele losses on chromosome 17 in human epithelial ovarian carcinoma. 57 61
2250917 1990
31
An oncogenic chromosome 8-9 gene fusion isolated following transfection of human ovarian carcinoma cell line DNA. 57 61
1973829 1990
32
Cytogenetic studies in ovarian cancer. 61 57
6690026 1984
33
Familial ovarian carcinoma. 61 57
4320145 1970
34
Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials-an ovarian cancer exemplar. 61 42
33494753 2021
35
Adenylate kinase 7 is a prognostic indicator of overall survival in ovarian cancer. 42 61
33429787 2021
36
Effect of traditional Chinese medicine (TCM) on survival, quality of life, and immune function in patients with ovarian carcinoma: A protocol for systematic review and meta analysis. 42 61
33466133 2021
37
Germline-Activating RRAS2 Mutations Cause Noonan Syndrome. 6
31130285 2019
38
Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome. 6
31130282 2019
39
Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. 57
31043742 2019
40
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. 6
26266985 2015
41
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 6
26266975 2015
42
Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. 57
23467088 2013
43
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. 6
23100325 2013
44
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. 6
22658544 2012
45
De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. 6
22729223 2012
46
De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. 6
22729224 2012
47
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. 6
22729222 2012
48
A mosaic activating mutation in AKT1 associated with the Proteus syndrome. 6
21793738 2011
49
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. 57
20826764 2010
50
Diverse somatic mutation patterns and pathway alterations in human cancers. 57
20668451 2010